THE RISKS OF USING TRANEXAMIC ACID AND VITAMIN K FOR DECREASING PROTHROMBIN TIME AND ACTIVATED PARTIAL THROMBOPLASTIN TIME VALUES IN INTRACRANIAL HEMORRHAGIC PATIENTS AT RUMAH SAKIT UMUM PUSAT FATMAWATI JAKARTA
DOI:
https://doi.org/10.22159/ajpcr.2017.v10s5.23117Keywords:
Tranexamic acid, Vitamin K, Anticoagulant, Prothrombin time, Activated partial thromboplastin timeAbstract
Objective: Intracranial hemorrhaging is a life-threatening condition that requires intensive treatment. Such hemorrhaging can happen spontaneously and may be caused by vascular malformations, trauma, or the administration of anticoagulant medications. The purpose of this study was to evaluate the risks of using tranexamic acid and Vitamin K for decreasing prothrombin time (PT) and activated partial thromboplastin time (aPTT) values in intracranial hemorrhagic patients.
Methods: This study used a retrospective cohort design, and data were taken from patients' medical records at the medical record installation of Rumah Sakit Umum Pusat Fatmawati in Jakarta. A total of 125 medical records were selected based on the inclusion criteria. The first group included patients receiving only tranexamic acid, and the second group consisted of patients receiving both tranexamic acid and Vitamin K.
Results: Statistical analysis using Chi-squared testing for the first group showed a significant decrease in aPTT values, with p=0.000 (p<0.05), but there was no significant decrease in PT values, with p=0.314 (p<0.05). Statistical analysis using Chi-squared testing in the second group showed a significant decrease in aPTT values, with p=0.000 (p<0.05), and a significant decrease in PT values, with p=0.034 (p<0.05). Patients that used tranexamic acid and Vitamin K decreased the PT and aPTT values 2.7 times and 1, 6 times greater than patients without tranexamic acid and Vitamin K. Patients that used tranexamic acid decreased the PT and aPTT values 2.5 times and 1.2 times greater than patients without tranexamic acid.
Conclusions: The combination of tranexamic acid and Vitamin K is potentially more effective in decreasing of hemorrhaging.
Downloads
References
Kamal AH, Tefferi A, Pruthi RK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 2007;82(7):864-73.
Murray D, Pennell B, Olson J. Variability of prothrombin time and activated partial thromboplastin time in the diagnosis of increased surgical bleeding. Transfusion 1999;39(1):56-2.
McHugh J, Holt C, O’Keeffe D. An assessment of the utility of unselected coagulation screening in general hospital practice. Blood Coagul Fibrinolysis 2011;22(2):106-9.
Wang Y, Wang X, Kong Y, Li F, Chen H. Retrospective analysis of the predictive effect of coagulogram on the prognosis of intracerebral hemorrhage. Acta Neurochir Suppl 2011;111:383-5.
Chen H, Li F, Wang X, Kong Y, Wang Y. Retrospective analysis of the predictive effect of routine biochemical results on the prognosis of intracerebral hemorrhage. Acta Neurochir Suppl 2011;111:403-6.
Misbach J, Ali W. Stroke in Indonesia: A first large prospective hospital-based study of acute stroke in 28 hospitals in Indonesia. J Clin Neurosci 2001;8(3):245-9.
Stafford DW. The vitamin K cycle. J Thromb Haemost 2005;3(8):1873-8.
Ferland G. The discovery of vitamin K and its clinical applications. Ann Nutr Metab 2012;61(3):213-8.
Tie JK, Stafford DW. Structural and functional insights into enzymes of the vitamin K cycle. J Thromb Haemost 2016;14(2):236-47.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
